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  Purpose: This study was designed to investigate the  
validity of a single immunochemical fecal occult blood 
test (FOBT) for detection of colorectal neoplasia.
  Materials and Methods: A total of 3,794 average-risk
screenees and 304 colorectal cancer patients admitted to 
the National Cancer Center, Korea, between May 2001 and 
November 2002, were studied prospectively. All scree-
nees and admitted patients underwent FOBT and total 
colonoscopic examinations. Stools were self-collected, 
and examined using an immunochemical fecal occult 
blood test (OC-hemodiaⓇ, Eiken Chemical Co. Tokyo, 
Japan) and an OC-sensor analyzerⓇ (Eiken Chemical Co. 
Tokyo, Japan).
  Results: Of the 3,794 asymptomatic screenees, the 
colonoscopy identified colorectal adenomas and cancers 
in 613 (16.2%) and 12 (0.3% ) subjects, respectively. The 
sensitivities of a single immunochemical FOBT for detec- 
ting colorectal cancers and adenomas in screenees were
25.0 and 2.4% , respectively. The false positive rate of 
FOBT for colorectal cancer in screenees was 1.19%. For 
the total 316 colorectal cancer cases (including 12 cases 
from screenees), the FOBT sensitivities according to the 
T-stage were 38.5, 75.0%, 78.9 and 79.2%  for T1, 2, 3 and
4 cancers, respectively. The sensitivities according to the 
Dukes stages A, B and C were 63.4, 79.3 and 78.6%, re -
spectively.
  Conclusion: The sensitivities of a single immunoche-
mical FOBT for detecting colorectal cancers and adeno-
mas in screenees were 25.0 and 2.4% , respectively. The 
sensitivities of FO BT were about 80%  for D ukes B or 
C  colorecta l cancers and 63.4%  for D ukes A. (C ancer 
R esearch and  Treatment 2005;37:20-23)
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INTRODUCTION
 
  Colorectal cancer is common in the Western world, and a 
significant cause of death. In Eastern Europe, Japan and Korea, 
although the incidence of colorectal cancer is lower than that 
in Western countries, a sharp increase in cases has occurred 
(1～3).
  Despite its increasing incidence, treatments for advanced 
colorectal cancer are not satisfactory. Currently, the ideal method 
for decreasing mortality from colorectal cancer is early detec-
tion of the malignancy (4,5).
  Screening methods for colorectal cancer include the fecal 
occult blood test (FOBT), barium enema, sigmoidoscopy and 
colonoscopy. Large randomized controlled trials have shown 
that FOBT screening can result in decreased colorectal cancer 
mortality (6～8). However, using FOBT, the rates of false 
positive and false negative results are too high, and the sensi-
tivities for detecting early stage colorectal cancer or adenoma 
are not satisfactory. Immunochemical modifications have 
recently been introduced to overcome these limitations to 
conventional guaiac-based FOBT (9,10).
  Here, we report on a study designed to investigate the 
validity of a single immunochemical fecal occult blood test for 
the detection of colorectal neoplasia.
MATERIALS AND METHODS
  Three thousand seven hundred and ninety four asymptomatic 
average-risk screenees, and three hundred and four colorectal 
cancer patients, admitted to the National Cancer Center, Korea, 
between May 2001 and November 2002 were studied pro-
spectively. All screenees and colorectal cancer patients under-
went FOBT and total colonoscopic examinations.
  In the screenee group, all subjects visited the Center for 
Cancer Prevention & Detection, the National Cancer Center, 
Korea, for a medical check-up. The subjects with a previous 
colorectal pathology, such as colorectal cancers or polyps, and 
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Table 2. The sensitivity and specificity of immunochemical fecal occult blood for detecting colorectal neoplasia (adenoma or cancer) in 
asymptomatic screenees by gender and age
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Male Female
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Age (years) n Incidence (%) Sensitivity (%) Specificity (%) n Incidence (%) Sensitivity (%) Specificity (%)
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  ～39 391  6.1 12.5 98.4 300 2.3 0 99.3
40～49 760 14.6   0 98.9 582  8.4 0 99.6
50～59 617 29.3 2.8 98.6 514 11.9 0 98.2
60～69 317 32.3 3.7 97.8 233 20.6 2.0 98.9
70～ 45 35.6 12.5  100  14 50.0 0 100
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Table 1. General characteristics of the study population
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Screenee group Patient group
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
Number 3794 304
Male：Female 1.3：1 1.6：1
Mean age (years) 48.9 59.6
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who had a family history of FAP or HNPCC were excluded. 
Subjects with recent colorectal symptoms, such as abdominal 
pain, diarrhea, constipation and hematochezia, were also 
excluded.
  All three hundred and four colorectal cancer patients under-
went colorectal resection surgery at the Center for Colorectal 
Cancer, the National Cancer Center, Korea. The tumor speci-
mens were pathologically classified by T and Dukes stages 
(11).
  For the total colonoscopic examination, the colonoscope was 
inserted as far as the cecum, with all the colorectal mucosae 
examined. Excluded from the study were cases where the 
colonoscope failed to reach the cecum and where poor bowel 
preparation prevented evaluation of the entire colorectal 
mucosae. All neoplasms detected during colonoscopy were 
biopsied or removed using the conventional polypectomy 
methods of snaring or hot biopsy, and all retrieved specimens 
examined pathologically.
  High-risk adenomas were defined as adenomas with high 
grade dysplasia, a 10 mm or greater diameter or with at least 
25% villous components.
  All stools were collected by a conventional self-collection 
method prior to the colonoscopic examinations. Screenees and 
patients received a stool-collecting bottle, and collected stools 
by self-sampling. There were no dietary or medicinal restric-
tions. Stools were examined by immunochemical FOBT, using 
an OC-hemodiaⓇ (Eiken Chemical Co. Tokyo, Japan) and an 
OC-sensor analyzerⓇ (Eiken Chemical Co. Tokyo, Japan). A 
positive FOBT result was defined as ＞100 ng/ml fecal 
hemoglobin.
  The sensitivity of FOBT was defined as the positive rate of 
the FOBT in the group with colorectal adenomas or cancers 
confirmed by total colonoscopic examination. The specificity of 
FOBT in the screenees was defined as the negative rate of the 
FOBT in the group without colorectal neoplasia, as confirmed 
by the total colonoscopic examination. A false positive FOBT 
in the screenees was defined as a positive FOBT result, but 
with no colorectal adenoma or cancer detected by the total 
colonoscopic examination. A false negative FOBT in the 
screenees was defined as a negative FOBT result, but with 
colorectal neoplasia detected by the total colonoscopic ex-
amination. The positive predictive value of FOBT was defined 
as the probability that a person with a positive FOBT result 
had an adenoma or cancer according to the colonoscopy. The 
negative predictive value of FOBT was defined as the 
probability that a person with a negative test without an ade-
noma or cancer according to the colonoscopy.
  Statistical significance was evaluated using the chi-squared 
test, with a two-tailed p value less than 0.05 defined as statis-
tically significant.
RESULTS
  Of the three thousand seven hundred and ninety four asymp-
tomatic average-risk screenees, 2151 were men and 1643 
women, with a mean age of 48.9 years, ranging from 15 to 
78 years (Table 1). The colonoscopies on the screenees showed 
613 (16.2%) had colorectal adenomas and 67 (1.8%) high-risk 
adenomas. Colorectal cancers were detected in 12 (0.3%) 
screenees.
  FOBT on these screenees showed a positive rate of 1.4%. 
The sensitivities of FOBT in detecting adenomas, high-risk 
adenomas and cancer were 2.4, 6.0 and 25.0%, respectively.
  The false positive and negative rates of FOBT for colorectal 
adenomas or cancer were 1.19 and 97.6%, respectively. The 
positive and negative predictive values of the test were 28.3 
and 84.0%, respectively.
  The sensitivities and specificities of FOBT by gender and age 
of the screenees are listed in Table 2.
  Of the three hundred and four colorectal cancer patients, 186 
were men and 118 women, with a mean age of 59.6 years, 
ranging from 27 to 85 years (Table 1). The overall sensitivity 
of FOBT in these cases was 78.3%. Of the total 316 colorectal 
cancer cases (including the 12 cases from the screenees), the 
sensitivities according to T-stage were 38.5, 75.0, 78.9 and 
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Table 3. The sensitivities of a single immunochemical fecal occult 
blood test by T stage of colorectal cancer
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 n Sensitivity (%) p
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T1  13 38.5
T2  40 75.0 ＜0.05
T3 191 78.9
T4  72 79.2
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Table 4. The sensitivities of a single immunochemical fecal occult 
blood test by Dukes stage of colorectal cancer
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n Sensitivity (%) p
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Dukes A  41 63.4
Dukes B  92 79.3 ＜0.05
Dukes C 183 78.6
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79.2% for T1, 2, 3 and 4 cancers, respectively, with that for 
T1 tumors significantly lower than those for T2, 3 and 4 tumors 
(p＜0.05) (Table 3).
  When classifying the tumors according to Dukes stage, the 
FOBT sensitivities were 63.4, and 78.6% for Dukes stages A, 
B and C, respectively, with that for Dukes A significantly lower 
than those for Dukes B and C (p＜0.05) (Table 4). 
DISCUSSION
  Screening asymptomatic people for colorectal cancer can 
reduce mortality from this disease. Many experts recommend 
various screening tools for the average-risk population over 50 
years of age, namely FOBT, sigmoidoscopy, barium enema and 
colonoscopy (12,13). Among these screening tools, FOBT has 
been shown to be effective in reducing mortality from colon 
cancer in large randomized controlled trials, and is relatively 
cheap, easy to perform and non-invasive (6～8,14). However, 
FOBT is known to have low sensitivities for early stage 
colorectal cancer and adenomas. Several modifications have 
been attempted in order to overcome the deficiencies of the 
FOBT, including guaiac methods, with rehydration techniques 
and immunochemical methods (9,10,15).
  Lieberman and Weiss (16) reported the sensitivity for the 
fecal occult blood test alone, for any neoplasia, was 11.7%, 
with that for advanced neoplasia (adenoma 10 mm or greater 
in diameter, at least 25% villous, high grade dysplasia or a 
classified invasive cancer) was 23.9%. They used a method 
involving guaiac-impregnated cards (Hemoccult II) and rehyd-
ration. Nakama et al. (17) reported the sensitivities for the 
one-day immunochemical FOBT for colorectal cancer and 
adenomas were 55.6 and 30.1% respectively. They also re-
ported the sensitivities for colorectal cancer were 83.3 and 
88.9% for the two- and three-day methods, respectively (17). 
Although the sensitivity of FOBT was higher than with the 
two- or three-day methods used in previous studies, we 
investigated the diagnostic validity of FOBT using the one-day 
method, which is convenient and widely used for colorectal 
cancer screening in Korea.
  In our study, we used an immunochemical FOBT, which is 
more sensitive than conventional guaiac-based FOBT (18). Our 
data show a single immunochemical FOBT in asymptomatic 
average-risk screenees had sensitivities of 25.0 and 2.4% for 
colorectal cancer and colorectal adenomas, respectively. The 
sensitivities for colorectal cancer and adenomas in our study 
were lower than those in previous studies (9,10,15～18). This 
may have been because in the present study, total colonoscopies 
and FOBT were performed on all asymptomatic screenees, 
which led to a greater detection rate of early stage colorectal 
cancer. However, from our results, the sensitivity for colorectal 
cancer in the admitted group was 78.3%, which was not much 
different from the other studies showing the sensitivity of 
immunochemical FOBT for colorectal cancer (19). Also, of the 
12 detected colorectal cancer cases in the asymptomatic aver-
age-risk screenee group, 4 (30%) were identified with Dukes 
stage A cancers, whereas 37 (12.2%) were identified to Dukes 
stage A cancers in the 304 admitted colorectal cancer patients, 
and this difference was found to be statistically significant (p＜
0.05).
  The sensitivity and specificity of the fecal occult blood test 
are affected by the cut-off values and fecal collection time. 
Physiologic blood loss from the gastrointestinal tract has been 
estimated to be 0.32±0.09 mg/g stool (20). Nakama et al. (21) 
reported that 150 ng/ml of fecal hemoglobin was the optimal 
cut-off point when carrying out the OC-hemodia test as a 
means of screening for colorectal cancer, but no significant 
difference was observed in the specificities between 50 and 150 
ng/ml. In our study, a positive FOBT result was defined as ＞
100 ng/ml fecal hemoglobin. When using this lower cut-off 
point, the sensitivity of FOBT can be increased. However, the 
optimal cut-off point must be calculated by the positive 
predictive value, receiver operating characteristic (ROC) curve 
and from a cost-effectiveness analysis. Further study is required 
to evaluate the cost-effectiveness and validity of immunoche-
mical FOBT.
  Early detection of early stage colorectal cancer has recently 
been emphasized as the ideal method for increasing the survival 
rates and quality of life. Despite the importance of research for 
early stage colorectal cancer detection, it has largely been 
limited to colonoscopic diagnosis and management. In the 
National Polyp Study (22), patients who underwent colo-
noscopy and removal of all polyps had a lower incidence of 
colorectal cancer during six years of follow-up than reference 
populations. There is no doubt that colonoscopy is the best 
method for detecting colorectal cancer or adenomas, and a 
synchronous colorectal pathology (22,23). However, this pro-
cedure is invasive, expensive and requires skillful endoscopists 
(14,24). In addition, it has not yet been proven that a 
colonoscopic examination reduces the rate of mortality from 
colorectal cancer any more than other screening tools.
  Of the current screening tools for colorectal cancer, FOBT 
has been proved to reduce the mortality from colorectal cancer 
in large randomized controlled trials (6～8). However, the 
present study indicates a single immunochemical FOBT is not 
sufficient for detection of colorectal cancer in screenees. 
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Further work will be required in order to identify the ideal 
screening tools for detection of colorectal cancer in order to 
decrease the mortality from this disease.
CONCLUSIONS
  The sensitivities of a single immunochemical FOBT for 
detecting colorectal cancers and adenomas in screenees were 
25.0 and 2.4%, respectively. The sensitivities according to 
Dukes stage were 63.4, 79.3 and 78.6% for Dukes A, B and 
C, respectively. These findings indicate that about one-third of 
Dukes A colorectal cancers appear to be undetected by a single 
immunochemical FOBT screen.
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